Clinical Trial Update: Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and tolerability of an oral extended-release parnaparin sodium formulation as add-on therapy in Ulcerative Colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Parnaparin sodium extended-release formulation (Parnaparin sodium)

Snippet

Sponsor: Cosmo Technologies Ltd | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED